The most important take-home information from the INTERLACE trial is that in some people with cervical cancer that are ...
Chemotherapy regimen shows potential to improve survival and reduce need for surgery in patients with muscle-invasive bladder ...
OS Therapies (NYSE:OSTX) is up ~65% in premarket trading Wednesday after releasing phase 2b data on OST-HER2 for prevention ...
The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...
Oral cancer is an increasingly prevalent disease worldwide, with over 300,000 new cases diagnosed each year. Among oral ...
Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...
A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...
The platinum chemotherapy shortage resulted in a modest absolute reduction in platinum use but no difference in mortality, data suggest.
For two years at Bard, Sage studied how Cisplatin, a chemotherapy drug, interacts with RNA in RNA-DNA hybrid structures.
Neoadjuvant chemotherapy followed by transoral robotic surgery (NECTORS) and neck dissection led to better survival outcomes ...